glp 1 alzheimer's GLP-1R agonists protect against disease by rewiring energy regulation GLP-1 Drug Fails to Quell

Increases in sympathetic outflow remain the largest safety concern for melanocortin agonists after compounds such as LY2112688 and bremelanotide demonstrated increases in both blood pressure and heart rate in clinical trials (16, 150)

Its not clear if there is something unique about this class of drugs that leads to specific outcomes on the muscle, whether its a loss of mass or an improvement in muscle function and performance

Under Article 4.5 of the World Anti-Doping Code, WADA is required to establish a monitoring programme of substances that are not on the List, but that WADA wishes to monitor in order to detect patterns of misuse in sport

Consult your doctor before trying unproven therapies and never use them as a replacement for conventional treatments